FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Expires: February 28, 2011
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public
Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

ESBER HENRY JEMIL 		2. Issuer Name and Ticker or Trading Symbol

NEXMED INC [ NEXM ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
EVP Pre-Clinical Business Dev.
(Last)          (First)          (Middle)

C/O NEXMED, INC., 6330 NANCY RIDGE DRIVE, SUITE 103 		3. Date of Earliest Transaction (MM/DD/YYYY)

6/21/2010
(Street)

SAN DIEGO, CA 92121
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   6/21/2010     A (1)    233752   A $2.52   381870   D    
Common Stock   6/21/2010     A (2)    119873   A $2.52   192412   I   By wife  

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
( 1)  Pursuant to the terms of the promissory note in the principal amount of $1,351,042.88 (the "Note") issued by the Issuer under the Agreement and Plan of Merger, dated as of November 20, 2009, by and among the Issuer, BQ Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of the Issuer, Bio-Quant, Inc., a Utah corporation, and certain other parties listed therein (the "Merger Agreement"), the Issuer has elected to repay a portion of the principal and accrued interest outstanding under the Note through the issuance of 233,752 shares of the Issuer's Common Stock, par value $0.001 per share, as permitted and on the terms set forth in the Note.
( 2)  Pursuant to the terms of the promissory note in the principal amount of $692,842.50 (the "Note") issued by the Issuer under the Merger Agreement, the Issuer has elected to repay a portion of the principal and accrued interest outstanding under the Note through the issuance of 119,873 shares of the Issuer's Common Stock, par value $0.001 per share, as permitted and on the terms set forth in the Note.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
ESBER HENRY JEMIL
C/O NEXMED, INC.
6330 NANCY RIDGE DRIVE, SUITE 103
SAN DIEGO, CA 92121 		X
EVP Pre-Clinical Business Dev.

Signatures
/s/ Mark Westgate, by power of attorney for Henry J. Esber 6/25/2010
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Nexmed (MM) (NASDAQ:NEXMD)
Historical Stock Chart
From Feb 2025 to Mar 2025 Click Here for more Nexmed (MM) Charts.
Nexmed (MM) (NASDAQ:NEXMD)
Historical Stock Chart
From Mar 2024 to Mar 2025 Click Here for more Nexmed (MM) Charts.